Action Gentium Spa - GNT

Outils de qualité professionnelle, pour des investisseurs individuels.

Premium

Dernier

Prix Achat

Prix Vente

Volume échangé

0,00 Fourchette du Jour 0,00

0,00 Plage de 52 semaines 0,00

Clôture Veille

Ouverture

Dernière Transaction

Dernière heure de transaction

Volume moyen (3 m)

Volume financier

VWAP

Gentium Begins Trading on NASDAQ; New Ticker Symbol: GENT

Gentium S.p.A. (NASDAQ:GENT)(AMEX:GNT) (the Company) today announced that its American Depository Shares (ADSs) will be listed and begin trading today on the NASDAQ National Market System under...

Gentium to Trade on NASDAQ National Market

Gentium S.p.A. (AMEX: GNT) (the Company) today announced that effective May 16, 2006, the Company's American Depository Shares (ADSs) will be listed for trading on The NASDAQ National Market...

Gentium Reports 2005 Financial Results; Provides Financial and Clinical Update

Gentium S.p.A. (AMEX:GNT) (the "Company") today reported financial results for the quarter and year ended December 31, 2005. Highlights of the fourth quarter of 2005 and recent weeks as of...

Gentium Receives First IRB Approval to Begin U.S. Phase III Trial with Defibrotide to Treat Veno-Occlusive Disease with Multipl

Dana-Farber/Harvard Cancer Center, Massachusetts General Hospital, Beth Israel Deaconess Medical Center and The Children's Hospital Receive IRB Approval to Commence Study ? Gentium S.p.A...

Gentium to Present at Angiogenesis in Cancer and Vascular Disease Congress; Defibrotide Has Anti-Angiogenic Properties In Vitro

Gentium S.p.A. (AMEX:GNT) (the "Company") today reported that on February 7, 2006, Guenther Eisser, Chief of Biology Research for Gentium, will present a poster entitled, "Defibrotide...

Gentium's Defibrotide Subject of Independent Study in Japan; First Japanese Study Reports That Defibrotide Shows Success Treatin

Gentium S.p.A. (AMEX:GNT) (the "Company") today reported that an independent study of Defibrotide was the subject of a published paper titled "Successful Treatment with Defibrotide for Sinusoidal...

Gentium Initiates Phase II/III Pediatric Trial with Defibrotide to Prevent Veno-Occlusive Disease; European Group for Blood and

Gentium S.p.A. (AMEX:GNT) (the "Company") today announced the initiation of a Phase II/III trial with Defibrotide to prevent Veno-Occlusive Disease ("VOD"), a complication of bone marrow and stem...

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	DE
4	0	0	0	0	0	0	0	DE
12	0	0	0	0	0	0	0	DE
26	0	0	0	0	0	0	0	DE
52	0	0	0	0	0	0	0	DE
156	0	0	0	0	0	0	0	DE
260	0	0	0	0	0	0	0	DE

Volume
% Gagnants
% Perdants

Symbole	Prix	Vol.
PSFFPacer Swan SOS Fund of Funds ETF	US$ 45,00 (54,37%)	1
BBLUEa Bridgeway Blue Chip ETF	US$ 20,00 (52,56%)	4
SOARVolato Group Inc	US$ 0,3206 (51,94%)	15,58M
MUSTColumbia Multi sector Municipal Income ETF	US$ 30,00 (45,35%)	1
QLTYGMO US Quality ETF	US$ 44,00 (36,94%)	1
BKTIBK Technologies Corporation	US$ 24,00 (-27,16%)	106
ITPIT Tech Packaging Inc	US$ 0,1911 (-15,81%)	12,85k
ATCHAtlasClear Holdings Inc	US$ 0,1872 (-14,83%)	521,37k
ZONECleanCore Solutions Inc	US$ 1,51 (-11,70%)	6,26k
DDCDDC Enterprise Limited	US$ 0,1651 (-10,90%)	123,18k
SOARVolato Group Inc	US$ 0,3206 (51,94%)	15,58M
MSTZT Rex 2X Inverse MSTR Daily Target ETF	US$ 1,35 (0,00%)	4,11M
SOXLDirexion Daily Semiconductor Bull 3X Shares	US$ 27,81 (0,51%)	2,22M
UVIX2x Long VIX Futures ETF	US$ 3,98 (11,17%)	1,75M
NVDQT Rex 2X Inverse NVIDIA Daily Target ETF	US$ 3,26 (-2,25%)	809,73k

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Gentium Spa Ads (GNT)

Outils de qualité professionnelle, pour des investisseurs individuels.

Statistiques et détails clés

GNT Dernières nouvelles

Gentium Begins Trading on NASDAQ; New Ticker Symbol: GENT

Gentium to Trade on NASDAQ National Market

Gentium Reports 2005 Financial Results; Provides Financial and Clinical Update

Gentium Receives First IRB Approval to Begin U.S. Phase III Trial with Defibrotide to Treat Veno-Occlusive Disease with Multipl

Gentium to Present at Angiogenesis in Cancer and Vascular Disease Congress; Defibrotide Has Anti-Angiogenic Properties In Vitro

Gentium's Defibrotide Subject of Independent Study in Japan; First Japanese Study Reports That Defibrotide Shows Success Treatin

Gentium Initiates Phase II/III Pediatric Trial with Defibrotide to Prevent Veno-Occlusive Disease; European Group for Blood and

Gentium Reports Third Quarter Financial Results; Provides Financial and Clinical Update

Gentium to Present at Rodman & Renshaw Techvest Seventh Annual Healthcare Conference

Gentium Completes $10.9 Million Private Placement

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	DE
4	0	0	0	0	0	0	0	DE
12	0	0	0	0	0	0	0	DE
26	0	0	0	0	0	0	0	DE
52	0	0	0	0	0	0	0	DE
156	0	0	0	0	0	0	0	DE
260	0	0	0	0	0	0	0	DE

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	DE
4	0	0	0	0	0	0	0	DE
12	0	0	0	0	0	0	0	DE
26	0	0	0	0	0	0	0	DE
52	0	0	0	0	0	0	0	DE
156	0	0	0	0	0	0	0	DE
260	0	0	0	0	0	0	0	DE

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Gentium Spa Ads (GNT) Cours

Gentium Spa Ads (GNT)

Outils de qualité professionnelle, pour des investisseurs individuels.

Statistiques et détails clés

GNT Dernières nouvelles

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	DE
4	0	0	0	0	0	0	0	DE
12	0	0	0	0	0	0	0	DE
26	0	0	0	0	0	0	0	DE
52	0	0	0	0	0	0	0	DE
156	0	0	0	0	0	0	0	DE
260	0	0	0	0	0	0	0	DE